Journal: Cancers

Article Title: The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.

doi: 10.3390/cancers16040832

Figure Lengend Snippet: Figure 1. Efficacy of combination therapy of anti-CD47 antibody (Ab) and anti-CTLA4 Ab in non- small cell lung cancer (NSCLC) mouse models. C57BL/6 mice (n = 5–8 per group) bearing tumors of LLC cells were treated with control rat immunoglobulin G (IgG) (10 mg/kg) or administered with anti- CD47 Ab (10 mg/kg) and anti-CTLA4 Ab (10 mg/kg, three times weekly) alone or in combination. These treatments were administered intraperitoneally three times a week for 24 days. Tumor growth (A) and survival rates (B) were closely observed throughout the experimental period. (A) In non- small cell lung cancer (NSCLC) mouse models, tumor volume was presented after treatment with Anti-CD47 Ab, Anti-CTLA4 Ab or Anti-CD47 Ab plus Anti- CTLA4 Ab. (B) Kaplan-Meier survival distribution graph illustrating the impact of different treatments on mouse survival. Quantitative analysis of tumor volume is displayed as mean ± standard deviation (SD). (n = 5 per group). Ns, no significance; *** p < 0.001.

Article Snippet: The protein levels of CTLA4, Foxp1, and Ki-67 in tumor tissues were assessed using anti-CTLA4 Ab (BM5388; Boster, Pleasanton, CA, USA), anti-Foxp1 Ab (ab134055; Abcam), and anti-Ki-67 Ab (ab16667; Abcam).

Techniques: Control, Standard Deviation

Journal: Cancers

Article Title: The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.

doi: 10.3390/cancers16040832

Figure Lengend Snippet: Figure 2. Effect of dual CD47 and CTLA4 blockade on immune stimulation in non-small cell lung cancer NSCLC-bearing mice. Tumors of LLC cells were established in C57BL/6 mice, and these mice

Article Snippet: The protein levels of CTLA4, Foxp1, and Ki-67 in tumor tissues were assessed using anti-CTLA4 Ab (BM5388; Boster, Pleasanton, CA, USA), anti-Foxp1 Ab (ab134055; Abcam), and anti-Ki-67 Ab (ab16667; Abcam).

Techniques:

Journal: Cancers

Article Title: The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.

doi: 10.3390/cancers16040832

Figure Lengend Snippet: Figure 3. Effect of Foxp1 on CTLA4 up-regulation after CD47 blockade in non-small cell lung cancer (NSCLC) cells. (A) The fraction of CTLA4+ cells in tumor tissues of LLC cells was evaluated

Article Snippet: The protein levels of CTLA4, Foxp1, and Ki-67 in tumor tissues were assessed using anti-CTLA4 Ab (BM5388; Boster, Pleasanton, CA, USA), anti-Foxp1 Ab (ab134055; Abcam), and anti-Ki-67 Ab (ab16667; Abcam).

Techniques:

Journal: Cancers

Article Title: The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.

doi: 10.3390/cancers16040832

Figure Lengend Snippet: Figure 6. Role of CD47 and CTLA4 combined targeted therapy on blood cell changes in non-small cell lung cancer (NSCLC)-bearing mice. C57BL/6 mice with subcutaneous tumors of LLC cells were treated with anti-CD47 antibody (Ab) alone, anti-CTLA4 Ab alone, combination therapy, and control IgG three times per week for 24 days. Blood samples (0.5 mL) were retrieved from the eyeball extirpating in each group and analyzed using an automatic hemocytometer. Changes in hemoglobin (A), the mean corpuscular hemoglobin concentration (B) and white blood cells (C), red blood cells (D), platelets (E), eosinophils (F). Data are expressed as mean ± standard error (SE). Data in (A–F) are evaluated with a one-way analysis of variance. * p < 0.05, ** p < 0.01, and *** p < 0.001; ns, not significant.

Article Snippet: The protein levels of CTLA4, Foxp1, and Ki-67 in tumor tissues were assessed using anti-CTLA4 Ab (BM5388; Boster, Pleasanton, CA, USA), anti-Foxp1 Ab (ab134055; Abcam), and anti-Ki-67 Ab (ab16667; Abcam).

Techniques: Control, Concentration Assay

Journal: Scientific reports

Article Title: Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma.

doi: 10.1038/s41598-025-88671-4

Figure Lengend Snippet: Fig. 9. Relative expression of genes expression in GBM tissues. Expression levels of WTAP and ZC3H13 genes were compared with those of the control group on GBM tissues, 10 GBM and adjacent tissues, respectively (A). The expression levels of siRNA WTAP and overexpression ZC3H13 genes (B and C). The expression levels of CD27, CD70, CD80, CD86, ICOS, CTLA4, and LAG3 in siRNA WTAP and overexpression ZC3H13 were demonstrated in Fig. 9D and F, respectively. The result were determined by qRT-PCR. The data are mean ± standard deviation of six replicate experiments. * P < 0.05, **P < 0.01 and ***P < 0.001 compared with the corresponding control values.

Article Snippet: After blocking with 5% nonfat milk, the membranes were immunoblotted with the primary antibodies: WTAP (A04296-2, Boster Biotech, Wuhan, China), CD27 (A01148-2, Boster Biotech), CD70 (A02853-2, Boster Biotech), CD80 (A00196-3, Boster Biotech), CD86(BM4121, Boster Biotech), ICOS (A00291-2, Boster Biotech), CTLA4 (A00020-1, Boster Biotech), LAG3 (M02869-2, Boster Biotech), Beta-actin (BM3873, Boster Biotech).

Techniques: Expressing, Control, Over Expression, Quantitative RT-PCR, Standard Deviation